These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
364 related articles for article (PubMed ID: 23762367)
1. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. Hanrahan CF; Selibas K; Deery CB; Dansey H; Clouse K; Bassett J; Scott L; Stevens W; Sanne I; Van Rie A PLoS One; 2013; 8(6):e65421. PubMed ID: 23762367 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495 [TBL] [Abstract][Full Text] [Related]
3. Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa. Van Rie A; Page-Shipp L; Hanrahan CF; Schnippel K; Dansey H; Bassett J; Clouse K; Scott L; Stevens W; Sanne I Int J Tuberc Lung Dis; 2013 Mar; 17(3):368-72. PubMed ID: 23407225 [TBL] [Abstract][Full Text] [Related]
4. Impact of a novel molecular TB diagnostic system in patients at high risk of TB mortality in rural South Africa (Uchwepheshe): study protocol for a cluster randomised trial. Lessells RJ; Cooke GS; McGrath N; Nicol MP; Newell ML; Godfrey-Faussett P Trials; 2013 Jun; 14():170. PubMed ID: 23758662 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of gene xpert for routine diagnosis of HIV-associated tuberculosis in Nigeria: A prospective cohort study. Akanbi MO; Achenbach C; Taiwo B; Idoko J; Ani A; Isa Y; Agbaji O; Ukoli C; Akande P; Maiga M; Murphy RL BMC Pulm Med; 2017 May; 17(1):87. PubMed ID: 28558662 [TBL] [Abstract][Full Text] [Related]
6. Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study. van Kampen SC; Tursynbayeva A; Koptleuova A; Murzakhmetova Z; Bigalieva L; Aubakirova M; Pak S; van den Hof S PLoS One; 2015; 10(7):e0132514. PubMed ID: 26181578 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Theron G; Peter J; van Zyl-Smit R; Mishra H; Streicher E; Murray S; Dawson R; Whitelaw A; Hoelscher M; Sharma S; Pai M; Warren R; Dheda K Am J Respir Crit Care Med; 2011 Jul; 184(1):132-40. PubMed ID: 21493734 [TBL] [Abstract][Full Text] [Related]
8. The effect of the Xpert MTB/RIF test on the time to MDR-TB treatment initiation in a rural setting: a cohort study in South Africa's Eastern Cape Province. Iruedo J; O'Mahony D; Mabunda S; Wright G; Cawe B BMC Infect Dis; 2017 Jan; 17(1):91. PubMed ID: 28109255 [TBL] [Abstract][Full Text] [Related]
9. Rapid diagnosis of pulmonary tuberculosis in African children in a primary care setting by use of Xpert MTB/RIF on respiratory specimens: a prospective study. Zar HJ; Workman L; Isaacs W; Dheda K; Zemanay W; Nicol MP Lancet Glob Health; 2013 Aug; 1(2):e97-e104. PubMed ID: 25104164 [TBL] [Abstract][Full Text] [Related]
10. Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. Di Tanna GL; Khaki AR; Theron G; McCarthy K; Cox H; Mupfumi L; Trajman A; Zijenah LS; Mason P; Bandason T; Durovni B; Bara W; Hoelscher M; Clowes P; Mangu C; Chanda D; Pym A; Mwaba P; Cobelens F; Nicol MP; Dheda K; Churchyard G; Fielding K; Metcalfe JZ Lancet Glob Health; 2019 Feb; 7(2):e191-e199. PubMed ID: 30683238 [TBL] [Abstract][Full Text] [Related]
11. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. Lawn SD; Brooks SV; Kranzer K; Nicol MP; Whitelaw A; Vogt M; Bekker LG; Wood R PLoS Med; 2011 Jul; 8(7):e1001067. PubMed ID: 21818180 [TBL] [Abstract][Full Text] [Related]
12. Tuberculosis Case Finding With Combined Rapid Point-of-Care Assays (Xpert MTB/RIF and Determine TB LAM) in HIV-Positive Individuals Starting Antiretroviral Therapy in Mozambique. Floridia M; Ciccacci F; Andreotti M; Hassane A; Sidumo Z; Magid NA; Sotomane H; David M; Mutemba E; Cebola J; Mugunhe RJ; Riccardi F; Marazzi MC; Giuliano M; Palombi L; Mancinelli S Clin Infect Dis; 2017 Nov; 65(11):1878-1883. PubMed ID: 29020319 [TBL] [Abstract][Full Text] [Related]
13. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. Cox HS; Mbhele S; Mohess N; Whitelaw A; Muller O; Zemanay W; Little F; Azevedo V; Simpson J; Boehme CC; Nicol MP PLoS Med; 2014 Nov; 11(11):e1001760. PubMed ID: 25423041 [TBL] [Abstract][Full Text] [Related]
14. Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial. Calligaro GL; Theron G; Khalfey H; Peter J; Meldau R; Matinyenya B; Davids M; Smith L; Pooran A; Lesosky M; Esmail A; Miller MG; Piercy J; Michell L; Dawson R; Raine RI; Joubert I; Dheda K Lancet Respir Med; 2015 Aug; 3(8):621-30. PubMed ID: 26208996 [TBL] [Abstract][Full Text] [Related]
15. Empiric treatment of pulmonary TB in the Xpert era: Correspondence of sputum culture, Xpert MTB/RIF, and clinical diagnoses. Kendall EA; Kamoga C; Kitonsa PJ; Nalutaaya A; Salvatore PP; Robsky K; Nakasolya O; Mukiibi J; Isooba D; Cattamanchi A; Kato-Maeda M; Katamba A; Dowdy DW PLoS One; 2019; 14(7):e0220251. PubMed ID: 31339935 [TBL] [Abstract][Full Text] [Related]
16. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa. Evans D; Sineke T; Schnippel K; Berhanu R; Govathson C; Black A; Long L; Rosen S BMC Health Serv Res; 2018 Dec; 18(1):973. PubMed ID: 30558670 [TBL] [Abstract][Full Text] [Related]
17. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Theron G; Zijenah L; Chanda D; Clowes P; Rachow A; Lesosky M; Bara W; Mungofa S; Pai M; Hoelscher M; Dowdy D; Pym A; Mwaba P; Mason P; Peter J; Dheda K; Lancet; 2014 Feb; 383(9915):424-35. PubMed ID: 24176144 [TBL] [Abstract][Full Text] [Related]
18. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Boehme CC; Nicol MP; Nabeta P; Michael JS; Gotuzzo E; Tahirli R; Gler MT; Blakemore R; Worodria W; Gray C; Huang L; Caceres T; Mehdiyev R; Raymond L; Whitelaw A; Sagadevan K; Alexander H; Albert H; Cobelens F; Cox H; Alland D; Perkins MD Lancet; 2011 Apr; 377(9776):1495-505. PubMed ID: 21507477 [TBL] [Abstract][Full Text] [Related]
19. Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa. Evans D; Schnippel K; Govathson C; Sineke T; Black A; Long L; Berhanu R; Rosen S PLoS One; 2017; 12(7):e0181238. PubMed ID: 28746344 [TBL] [Abstract][Full Text] [Related]
20. Performance of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis and rifampin resistance in a low-incidence, high-resource setting. Rice JP; Seifert M; Moser KS; Rodwell TC PLoS One; 2017; 12(10):e0186139. PubMed ID: 29016684 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]